BACKGROUND: Incorporation of the chimeric CD20 monoclonal antibody rituximab in the treatment schedule of patients with non-Hodgkin's lymphoma has significantly improved outcome. Despite this success, about half of the patients do not respond to treatment or suffer from a relapse and additional therapy is required. A low CD20-expression level may in part be responsible for resistance against rituximab. We therefore investigated whether the CD20-expression level related resistance to rituximab could be overcome by a new group of CD20 mAbs (HuMab-7D8 and ofatumumab) targeting a unique membrane-proximal epitope on the CD20 molecule. DESIGN AND METHODS: By retroviral transduction of the CD20 gene into CD20-negative cells and clonal selection of transduced cells a system was developed in which the CD20-expression level is the only variable. These CD20 transduced cells were used to study the impact of rituximab and HuMab-7D8 mediated complement-dependent cytotoxicity. To study the in vivo efficacy of these mAbs an in vivo imaging system was generated by retroviral expression of the luciferase gene in the CD20-positive cells. RESULTS: We show that HuMab-7D8 efficiently killed CD20(low) cells that are not susceptible to rituximab-induced killing in vitro. In a mouse xenograft model, we observed a comparable increase in survival time between HuMab-7D8 and rituximab-treated mice. Most significantly, however, HuMab-7D8 eradicated all CD20-expressing cells both in the periphery as well as in the bone marrow whereas after rituximab treatment CD20(low) cells survived. CONCLUSIONS: Cells that are insensitive to in vitro and in vivo killing by rituximab as the result of their low CD20-expression profile may be efficiently killed by an antibody against the membrane-proximal epitope on CD20. Such antibodies should, therefore, be explored to overcome rituximab resistance in the clinic.
BACKGROUND: Incorporation of the chimeric CD20 monoclonal antibody rituximab in the treatment schedule of patients with non-Hodgkin's lymphoma has significantly improved outcome. Despite this success, about half of the patients do not respond to treatment or suffer from a relapse and additional therapy is required. A low CD20-expression level may in part be responsible for resistance against rituximab. We therefore investigated whether the CD20-expression level related resistance to rituximab could be overcome by a new group of CD20 mAbs (HuMab-7D8 and ofatumumab) targeting a unique membrane-proximal epitope on the CD20 molecule. DESIGN AND METHODS: By retroviral transduction of the CD20 gene into CD20-negative cells and clonal selection of transduced cells a system was developed in which the CD20-expression level is the only variable. These CD20 transduced cells were used to study the impact of rituximab and HuMab-7D8 mediated complement-dependent cytotoxicity. To study the in vivo efficacy of these mAbs an in vivo imaging system was generated by retroviral expression of the luciferase gene in the CD20-positive cells. RESULTS: We show that HuMab-7D8 efficiently killed CD20(low) cells that are not susceptible to rituximab-induced killing in vitro. In a mouse xenograft model, we observed a comparable increase in survival time between HuMab-7D8 and rituximab-treated mice. Most significantly, however, HuMab-7D8 eradicated all CD20-expressing cells both in the periphery as well as in the bone marrow whereas after rituximab treatment CD20(low) cells survived. CONCLUSIONS: Cells that are insensitive to in vitro and in vivo killing by rituximab as the result of their low CD20-expression profile may be efficiently killed by an antibody against the membrane-proximal epitope on CD20. Such antibodies should, therefore, be explored to overcome rituximab resistance in the clinic.
Authors: J Golay; M Lazzari; V Facchinetti; S Bernasconi; G Borleri; T Barbui; A Rambaldi; M Introna Journal: Blood Date: 2001-12-01 Impact factor: 22.113
Authors: Mark S Cragg; Suzanne M Morgan; H T Claude Chan; B Paul Morgan; A V Filatov; Peter W M Johnson; Ruth R French; Martin J Glennie Journal: Blood Date: 2002-09-19 Impact factor: 22.113
Authors: Robert Marcus; Kevin Imrie; Philippe Solal-Celigny; John V Catalano; Anna Dmoszynska; João C Raposo; Fritz C Offner; José Gomez-Codina; Andrew Belch; David Cunningham; Elisabeth Wassner-Fritsch; George Stein Journal: J Clin Oncol Date: 2008-07-28 Impact factor: 44.544
Authors: Andrew W Pawluczkowycz; Frank J Beurskens; Paul V Beum; Margaret A Lindorfer; Jan G J van de Winkel; Paul W H I Parren; Ronald P Taylor Journal: J Immunol Date: 2009-06-17 Impact factor: 5.422
Authors: Rozemarijn S van Rijn; Elles R Simonetti; Anton Hagenbeek; Marieke C H Hogenes; Roel A de Weger; Marijke R Canninga-van Dijk; Kees Weijer; Hergen Spits; Gert Storm; Louis van Bloois; Ger Rijkers; Anton C M Martens; Saskia B Ebeling Journal: Blood Date: 2003-06-05 Impact factor: 22.113
Authors: Bruce A Peterson; Gina R Petroni; Glauco Frizzera; Maurice Barcos; Clara D Bloomfield; Nis I Nissen; David D Hurd; Edward S Henderson; George P Sartiano; Jeffrey L Johnson; James F Holland; Arlan J Gottlieb Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Erika M Cook; Margaret A Lindorfer; Hilma van der Horst; Simone Oostindie; Frank J Beurskens; Janine Schuurman; Clive S Zent; Richard Burack; Paul W H I Parren; Ronald P Taylor Journal: J Immunol Date: 2016-07-29 Impact factor: 5.422
Authors: Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle Journal: CNS Drugs Date: 2012-01-01 Impact factor: 5.749
Authors: Simone C Oostindie; Derek A Rinaldi; Gijs G Zom; Michael J Wester; Desiree Paulet; Kusai Al-Tamimi; Els van der Meijden; Jennifer R Scheick; Tessa Wilpshaar; Bart de Jong; Marloes Hoff-van den Broek; Rachel M Grattan; Janita J Oosterhoff; Julie Vignau; Sandra Verploegen; Peter Boross; Frank J Beurskens; Diane S Lidke; Janine Schuurman; Rob N de Jong Journal: Nat Biotechnol Date: 2022-07-25 Impact factor: 68.164